Feedback

Browsing by V

Use an asterisk (*) for partial word searches (e.g. pemph*)

77 results found.

1.
Ordering Recommendation:  

Use to detect common vaginal pathogens associated with vaginitis/vaginosis. Not recommended as stand-alone test for sexually transmitted infection testing or screening.

2.
3.
Ordering Recommendation:  

Preferred test for therapeutic drug management in patients with renal failure or conditions that may alter albumin concentrations.

4.
5.
6.
7.
8.
Ordering Recommendation:  

Screening culture to identify vancomycin-resistant enterococci (VRE) bacteria.

9.
Ordering Recommendation:  

Initial test for the diagnosis and monitoring of neuroblastoma.

10.
Ordering Recommendation:  

Initial test for the diagnosis and monitoring of neuroblastoma. Should be ordered concurrently with urine homovanillic acid test (0080422).

11.
Ordering Recommendation:  

Rapid diagnostic test with culture backup that may be helpful when uncertain whether a lesion is due to varicella-zoster (VZV) or herpes simplex virus (HSV).

12.
Ordering Recommendation:  

May aid in diagnosing acute infections and detecting past exposure and/or vaccination.

13.
Ordering Recommendation:  

Provide evidence of vaccination or past infection with varicella-zoster virus.

14.
Ordering Recommendation:  

Generally not recommended for the diagnosis of acute disease/encephalitis. May aid in diagnosing varicella-zoster virus vasculopathy.

15.
Ordering Recommendation:  

Panel that combines varicella-zoster virus IgG and IgM antibodies is preferred (0050162).

16.
Ordering Recommendation:  

Not recommended. Refer to varicella-zoster virus (VZV) PCR (0060042) or the meningitis/encephalitis PCR panel (2013305).

17.
Ordering Recommendation:  

Detect varicella-zoster virus in blood, CSF, ocular fluid, tissue, or vesicle fluid.

18.
Ordering Recommendation:  

Detect varicella-zoster virus (VZV). DFA sensitivity is highest when performed on scrapings from base of lesions. Molecular testing is generally preferred; refer to VZV by PCR (0060042).

19.
Ordering Recommendation:  

Detect varicella-zoster virus (VZV). Negative or inadequate DFA results are confirmed with culture. DFA sensitivity is highest when performed on scrapings from base of lesions; culture sensitivity is highest when specimens are collected soon after onset of symptoms. Molecular testing is generally preferred; refer to VZV by PCR (0060042).

20.
21.
Ordering Recommendation:  

Preferred DNA test to confirm clinical diagnosis of genetic related vascular malformations (ie, capillary malformation-arteriovenous malformation syndrome, cerebral cavernous malformation, glomuvenous malformation, hereditary hemorrhagic telangiectasia, juvenile polyposis syndrome/hereditary hemorrhagic telangiectasia, multiple cutaneous and mucosal venous malformations, Parkes Weber syndrome, PTEN-related Proteus syndrome).

22.
Ordering Recommendation:  

Acceptable DNA test to confirm clinical diagnosis of genetic related vascular malformations (ie, capillary malformation-arteriovenous malformation syndrome, cerebral cavernous malformation, glomuvenous malformation, hereditary hemorrhagic telangiectasia, juvenile polyposis syndrome/hereditary hemorrhagic telangiectasia, multiple cutaneous and mucosal venous malformations, Parkes Weber syndrome, PTEN-related Proteus syndrome).

23.
Ordering Recommendation:  

Aids in the diagnosis of VIPoma.

24.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

25.
Ordering Recommendation:  

Molecular (DNA) test to confirm a diagnosis of Very Long Chain Dehydrogenase (VLCAD) deficiency when Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (ACADVL) Sequencing (2002001) does not identify two causative mutations. Carrier testing for individuals with a family history of a deletion or duplication in the ACADVL gene.

26.
Ordering Recommendation:  

Molecular (DNA) test to diagnose or rule out Very Long Chain Dehydrogenase (VLCAD) deficiency following clinical and biochemical presentation. Also refer to Acylcarnitine Quantitative Profile, Plasma (0040033) and Organic Acids, Urine (0098389).

27.
Ordering Recommendation:  

Preferred molecular (DNA) test to diagnose or rule out Very Long Chain Dehydrogenase (VLCAD) deficiency following clinical and/or biochemical presentation. Also refer to Acylcarnitine Quantitative Profile, Plasma (0040033) and Organic Acids, Urine (0098389).

28.
Ordering Recommendation:  

Initial test to diagnose or rule out a peroxisomal disorder (such as Zellweger syndrome or X-linked adrenoleukodystrophy) following clinical and/or biochemical presentation.

29.
30.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

31.
Ordering Recommendation:  

Generally, virus-specific testing (eg, antigen detection or molecular) is recommended.

32.
Ordering Recommendation:  

For best results, specify specimen source and suspected virus on order form. Molecular diagnostics are preferred for suspected invasive CMV.

33.
Ordering Recommendation:  

Detects common respiratory viruses as well as HSV and VZV. Molecular methods may offer improved sensitivity. Respiratory Viruses Rapid Culture (2001504) offers faster turnaround time.

34.
Ordering Recommendation:  

Molecular diagnostics are preferred for suspected invasive CMV.

35.
Ordering Recommendation:  

Detect enterovirus, herpes simplex virus, or parechovirus, as etiological agents of meningitis.

36.
Ordering Recommendation:  

Detect cytomegalovirus, Epstein-Barr virus, herpes simplex virus, or varicella zoster virus as etiological agents of meningoencephalitis.

37.
Ordering Recommendation:  

Aids in the detection and subclassification of hyperandrogenism. Most useful in women and children with moderate/severe hirsutism or hirsutism of any degree when it is sudden in onset or rapidly progressive. Hirsutism Evaluation Panel is generally preferred.

38.
Ordering Recommendation:  

Aids in the detection of nonclassical congenital adrenal hyperplasia in individuals presenting with hyperandrogenism.

39.
Ordering Recommendation:  

Evaluate plasma hyperviscosity syndrome associated with disorders such as polycythemia, macroglobulinemia, multiple myeloma, and leukemia.

40.
Ordering Recommendation:  

Evaluate hyperviscosity syndrome associated with plasma cell dyscrasia.

41.
Ordering Recommendation:  

Use for nutritional assessment of vitamin A (retinol and retinyl palmitate) in serum or plasma.

42.
Ordering Recommendation:  

Do not use for evaluation of thiamine sufficiency. Refer to Vitamin B1 (Thiamine), Whole Blood (0080388) for nutritional assessment of thiamine.

43.
Ordering Recommendation:  

Use for nutritional assessment of vitamin B1 (thiamine).

44.
Ordering Recommendation:  

Aids in detection of vitamin B12 deficiency in individuals with macrocytic or unexplained anemia, or unexplained neurologic disease.

45.
Ordering Recommendation:  

Aids in detection of vitamin B12 and folate deficiency in individuals with macrocytic or unexplained anemia, or unexplained neurologic disease.

46.
47.
Ordering Recommendation:  

Not recommended for initial testing in suspected B12 deficiency. May be useful when B12 and MMA results alone are equivocal.

48.
Ordering Recommendation:  

Preferred test for evaluating vitamin B12 deficiency in individuals with macrocytic or unexplained anemia, or unexplained neurologic disease.

49.
Ordering Recommendation:  

Use for nutritional assessment of vitamin B2.

50.
51.
Ordering Recommendation:  

Use for nutritional assessment of vitamin B6.

52.
Ordering Recommendation:  

This test is NOT indicated for diagnosing patients with biotinidase deficiency or as a follow up of an abnormal newborn screen for biotinidase deficiency. Use in combination with other tests to confirm or monitor patients with biotinidase deficiency.

53.
Ordering Recommendation:  

Use for nutritional assessment of vitamin C.

54.
Ordering Recommendation:  

May be useful for evaluating calcium metabolism in individuals with hypercalcemia or renal failure in addition to Vitamin D, 25-Hydroxy testing. Test is not appropriate for diagnosing vitamin D deficiency or insufficiency.

55.
Ordering Recommendation:  

Preferred test to diagnose vitamin D insufficiency and monitor response to therapy. Testing is recommended only for patients at risk for vitamin D insufficiency.

56.
Ordering Recommendation:  

Use for nutritional assessment of vitamin E (alpha- and gamma-tocopherols).

57.
Ordering Recommendation:  

Use for nutritional assessment of vitamin K1.

58.
Ordering Recommendation:  

Aid in the evaluation of muscle weakness in the context neuromuscular junction disorder with or without cancer, or the diagnosis of paraneoplastic neurological syndromes.

59.
Ordering Recommendation:  

Screening test for voltage-gated potassium channel (VGKC) antibody receptor complex-associated autoantibodies. Assay does not identify contactin associated protein 2 (CASPR2) antibody or leucine-rich glioma inactivated 1 protein (LGI1) antibodies. Use to manage antibody-positive (VGKC, LGI1, or CASPR2) individual following immunotherapy and/or plasmapheresis.

60.
Ordering Recommendation:  

Screening test for voltage-gated potassium channel (VGKC) antibody receptor complex-associated autoantibodies with test reflex to CASPR2 and LGI1 antibodies. Antibodies are associated with acquired neuromyotonia, limbic encephalitis, painful neuropathy, Morvan syndrome, and rare tumors (eg, thymoma, small-cell lung cancer).

61.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from  ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

62.
Ordering Recommendation:  

Diagnostic testing for von Hippel-Lindau syndrome. Predictive testing for von Hippel-Lindau syndrome. Diagnostic testing for congenital polycythemia.

63.
Ordering Recommendation:  

Diagnostic testing for von Hippel-Lindau syndrome. Predictive testing for von Hippel-Lindau syndrome. Diagnostic testing for congenital polycythemia.

64.
Ordering Recommendation:  

Molecular testing to distinguish von Willebrand disease (vWD) type 2B from pseudo (platelet-type) vWD.

65.
Ordering Recommendation:  

Molecular testing to confirm a phenotypic diagnosis of von Willebrand disease type 2A.

66.
Ordering Recommendation:  

Molecular testing  to confirm a phenotypic diagnosis of von Willebrand disease type 2B and to distinguish from pseudo (platelet-type) vWD.

67.
Ordering Recommendation:  

Molecular testing  to confirm a phenotypic diagnosis of von Willebrand disease type 2M.

68.
Ordering Recommendation:  

Molecular testing to distinguish von Willebrand disease type 2N from hemophilia A. 

69.
Ordering Recommendation:  

Order in conjunction with von Willebrand Factor Antigen (0030285) and Factor VIII Activity (0030095) as part of initial workup of suspected von Willebrand disease.

70.
Ordering Recommendation:  

Order in conjunction with von Willebrand Factor Activity (Ristocetin Cofactor) (0030250) and Factor VIII Activity (0030095) as part of initial workup of suspected von Willebrand disease.

71.
Ordering Recommendation:  

Not an initial test in the diagnosis of von Willebrand disease (VWD). Ordering should be limited to specialists. Supplementary test for the subclassification of established VWD.

72.
Ordering Recommendation:  

Order to subclassify established von Willebrand disease.

73.
Ordering Recommendation:  

Order in conjunction with Factor VIII Activity (0030095) for the workup of suspected von Willebrand disease.

74.
Ordering Recommendation:  

Not recommended for initial screening except in suspected cases of acquired von Willebrand disease (vWD) or high suspicion of vWD. Preferred initial test is von Willebrand Panel with Reflex to von Willebrand Multimeric Analysis (2003387).

75.
Ordering Recommendation:  

Recommended panel for the initial workup of suspected von Willebrand disease.

76.
Ordering Recommendation:  

Recommended reflex panel to diagnose and subclassify suspected von Willebrand disease.

77.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.